Search Results

ABION (KOSDAQ: 203400) today released data from an ongoing Phase 2 trial of ABN401, the company’s wholly owned tyrosine kinase inhibitor intended to treat adult patients with advanced non-small cell lung cancer that exhibit the MET Exon 14 skipping mutation. In eight treatment-naïve patients, the objective response rate was 75% (6/8), and in the evaluable population of 17 patients, the objective response rate was 52.9% (9/17).

Swiss medtech company Abionic SA announced that they have developed the first COVID-19 severity test, the cSOFA (Covid Sequential Organ Failure Assessment) score, to help doctors quickly and accurately triage cases that come into emergency rooms.

Abionic SA, a Swiss Medtech firm based in Lausanne, has developed the cSOFA score, a tool to assess the severity of Covid-19.

Abionic SA, Swiss Medtech firm based in Lausanne, is initiating a pivotal clinical trial in the US for an innovative point-of-care diagnostic method for sepsis to validate the results of a first trial that took place in Europe in 2019, proving the suitability of Abionic’s sepsis test on the abioSCOPE® device to identify sepsis.

Abionic SA and Genentech announced a strategic agreement to develop and provide an In Vitro Diagnostic (IVD) Asthma Test Panel using Abionic’s POC abioSCOPE® platform in the United States.

Abionic SA announced the successful completion of its multi-center observational study using Abionic’s novel point-of-care Pancreatic Stone Protein sepsis test on the abioSCOPE® platform.

Abionic AB announced the successful closing of a CHF20 million Series C financing.

Abionic’s rapid allergy test, IVD CAPSULE Aeroallergens, and the easy to use testing platform, abioSCOPE have been registered in the United States by FDA..

Gerd Grenner, PhD, has more than 35 years’ experience in R&D management positions in medical diagnostics companies.